In an analysis involving 58,333 patients, semaglutide significantly reduced the one-year risk of heart failure hospitalization and all-cause mortality compared to sitagliptin in individuals with heart failure with preserved ejection fraction and type 2 diabetes. Tirzepatide also showed a decrease compared to sitagliptin but did not present significant benefits over semaglutide. The study utilized three U.S. claims databases to validate real-world outcomes and demonstrated consistent effects with previous clinical trials, underlining the importance of these agents in managing this patient population.

Source: JAMA